Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTP889 extended prophylaxis after hip fracture surgery
2004-002511-83Phase 2Completed
- Sponsor
- TransTech Pharma
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of TTP889 in venous thromboembolism (VTE) (2 arms), sponsored by TransTech Pharma. Primary endpoint: Occurrence of venous thromboembolism. Started Oct 2004; status: completed.
02
Drugs
TTP889
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2004-002511-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002511-83.